FDA recently issued another round of warning letters addressing compounded GLP-1 formulations and the way they are marketed to patients. According to public reporting, FDA objected to claims suggesting that certain compounded GLP-1 products were the same as, equivalent to, sourced from FDA-approved pharmacies, or clinically studied in the same way as commercially available GLP-1 drugs. This is not a new FDA concern in the peptide world. FDA’s message was direct: “Patients deserve to know what they’re getting.” The American Peptide Association agrees.
Patients should not be misled into believing that a compounded GLP-1 medication is FDA-approved, a generic equivalent, or the same as a commercially available branded drug. Marketing that obscures who is prescribing, who is compounding, where the medication is sourced, or what regulatory status applies does not support informed consent. It undermines it. Even more, as recent regulatory activity illustrates, it puts at risk the professional licenses of healthcare professionals relying on these products to move the needle in healthcare. False, deceptive or misleading advertising and marketing undermines the integrity of the industry and risks crushing access by consumers due to regulatory action that can work like a shotgun trying to kill a fly.
APA supports truthful advertising, transparent sourcing, responsible prescribing, and appropriate enforcement against false or misleading claims. So do ethical peptide enterprise participants. The commercial Pharma driven model itself isn’t perfect. Thousands of lawsuits have reportedly been filed involving even Pharma branded GLP-1 medications. Those claims are largely unresolved, and Pharma is circling their litigation wagons. But the existence of these reported cases reinforces a larger point: patient-safety questions will be at the forefront of both regulatory mindset and court driven activity. Accuracy (in marketing) and safety are the two watchwords for the industry.
One of the biggest trends we’re seeing is clinically driven peptide usage. A telehealth company springs up every day! When done with integrity, that trend should last. And integrity will consist at least of accurate education, clinical leadership and product transparency. And in the product segment of the industry , the time has never been better to data collect to illustrate safety and then to data translate to begin to prove outcomes (at least anecdotally).
Does that mean the end of the direct to consumer marketplace? We don’t think so. We don’t think regulators sincerely believe that the public should have no agency over issues of their healthcare and wellness and that they should be led only by clinicians (who are rarely trained in wellness). We don’t think any regulator intends to cut off the hands of the buying public. We believe instead that compromises in terms of marketing or safety will not (and should not) be tolerated. And that underscores the industry’s obligation to lead and codify safety and quality issues right now! The APA is committed to Safety, Quality and Access. And we understand the only way to “get there” is to lead ourselves as a community committed to making a positive impact in wellness.
Compounded medications from credible sources (both compound pharmacies and CGMP manufacturers) have a lawful and essential role in wellness. And the stain of misleading advertising cannot and should not be attributed to the entire industry. Clinicians and the public deserve to know what they are getting. They need a healthcare system where providers, pharmacists, manufacturers and consumers can work together, without fear or stigma, to make informed, safe and effective decisions.
Sources:
GLP-1 weight-loss drug lawsuits allege serious side effects;
US FDA sends 25 letters to telehealth companies over claims on compounded weight-loss drug